Health and Healthcare

Sequenom Files To Raise Capital (SQNM)

Sequenom, Inc. (NASDAQ: SQNM) has just filed to raise up to $150 million in a mixed securities shelf offering.  The diagnostics company could sell any combination of Common Stock, Preferred Stock, Debt Securities, and/or Warrants.

No underwriters were listed in the shelf offering and the company’s market cap is $411 million before the effects of this offering.

USE OF PROCEEDS: We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Unless otherwise indicated in any prospectus supplement, we intend to use the net proceeds from the sale of the securities under this prospectus for general corporate purposes, which may include research and development, capital expenditures, working capital, and general administrative expenses. We may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus….

As of September 30, 2011, Sequenom had more than $101 million spread out among is cash, cash equivalents, and short-term and long-term investments.  Long-term debt is only $11.67 million and total liabilities were only $42.1 million.

Sequenom shares are down over 3% at $4.01 after closing at $4.14 yesterday.  Be advised that the 52-week range is $3.95 to $8.71, so this is very close to a potential capital raise when shares are back at their weakest level in some time.

FULL SEC FILING

JON C. OGG

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.